Abstract
KVD900, an oral plasma kallikrein inhibitor, was evaluated in a phase 2, placebo-controlled, double-blind crossover trial in patients with hereditary angioedema (HAE) experiencing mild-to-moderate attacks. Given the lack of a “gold standard,” several patient-reported outcomes (PROs) were collected to capture the patient experience.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
